Real-world Glycemic Outcomes of a Tubeless Automated Insulin Delivery System (Medtrum A8 TouchCare) in Adults With Type 1 Diabetes

OBJECTIVES: Automated insulin delivery (AID) systems are recommended as a first-line therapy for type 1 diabetes. The Medtrum A8 TouchCare is a tubeless AID system powered by the APGO algorithm, which modulates basal insulin and delivers automatic correction microboluses. Real-world evidence on this system remains extremely limited. In this study, we aimed to evaluate the efficacy of the Medtrum A8 TouchCare in AID mode in a real-world cohort of adults with type 1 diabetes. METHODS: We conducted a single-centre, observational retrospective study at Federico II University Hospital, Naples, Italy (January to October 2025). Adults with type 1 diabetes of ≥6 months' duration who were using the Medtrum A8 TouchCare in AID mode were included. Continuous glucose monitoring metrics and clinical parameters were compared at baseline and after 3 months. The primary endpoint was the change in time in range. RESULTS: A total of 20 patients were included (mean age: 39±6 years; diabetes duration: 18±6 years). After 3 months, time in range increased by 12.51% (p